Radiant Logistics Inc (NYSEAMERICAN:RLGT) Shares Acquired by Scout Investments Inc.

Avalon Advisors LLC purchased a new position in Radiant Logistics in the first quarter worth about $1,730,000. Quantum Capital Management bought …

Radiant Logistics logoScout Investments Inc. boosted its holdings in shares of Radiant Logistics Inc (NYSEAMERICAN:RLGT) by 65.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 553,288 shares of the company’s stock after acquiring an additional 218,705 shares during the period. Scout Investments Inc. owned 1.12% of Radiant Logistics worth $3,397,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of RLGT. Avalon Advisors LLC purchased a new position in Radiant Logistics in the first quarter worth about $1,730,000. Quantum Capital Management bought a new stake in shares of Radiant Logistics in the first quarter worth approximately $1,674,000. Municipal Employees Retirement System of Michigan bought a new stake in shares of Radiant Logistics in the fourth quarter worth approximately $862,000. AJO LP grew its stake in shares of Radiant Logistics by 72.8% in the first quarter. AJO LP now owns 474,896 shares of the company’s stock worth $2,992,000 after acquiring an additional 200,142 shares during the period. Finally, BlackRock Inc. grew its stake in shares of Radiant Logistics by 5.6% in the fourth quarter. BlackRock Inc. now owns 2,513,781 shares of the company’s stock worth $10,684,000 after acquiring an additional 133,618 shares during the period. 39.47% of the stock is owned by institutional investors.

RLGT stock opened at $4.85 on Friday. Radiant Logistics Inc has a one year low of $4.01 and a one year high of $7.33.

Radiant Logistics (NYSEAMERICAN:RLGT) last released its earnings results on Thursday, May 9th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.08 by $0.03. The company had revenue of $206.05 million during the quarter, compared to analysts’ expectations of $234.84 million.

Several brokerages recently issued reports on RLGT. Cowen restated a “buy” rating and set a $7.00 target price on shares of Radiant Logistics in a research report on Monday, May 13th. Zacks Investment Research lowered shares of Radiant Logistics from a “buy” rating to a “hold” rating in a research report on Saturday, July 27th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Radiant Logistics presently has a consensus rating of “Buy” and a consensus price target of $7.42.

In other Radiant Logistics news, COO E Joseph Bento sold 9,779 shares of the business’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $6.53, for a total transaction of $63,856.87. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 23.30% of the stock is owned by corporate insiders.

About Radiant Logistics

Radiant Logistics, Inc operates as a third-party logistics and multi-modal transportation services company primarily in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services; and freight brokerage services, including truckload, less than truckload, and intermodal services.

Featured Article: Operating Income

Institutional Ownership by Quarter for Radiant Logistics (NYSEAMERICAN:RLGT)

Receive News & Ratings for Radiant Logistics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Radiant Logistics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Veeco Instruments (NASDAQ:VECO) Stock Rating Upgraded by ValuEngine

Two Sigma Investments LP boosted its stake in shares of Veeco Instruments by 197.3% during the 4th quarter. Two Sigma Investments LP now owns …

Veeco Instruments Inc. logoValuEngine upgraded shares of Veeco Instruments (NASDAQ:VECO) from a sell rating to a hold rating in a report released on Thursday, ValuEngine reports.

Several other research analysts also recently commented on the stock. Northland Securities reissued a buy rating and issued a $14.00 price target on shares of Veeco Instruments in a report on Monday, May 6th. Zacks Investment Research raised shares of Veeco Instruments from a hold rating to a strong-buy rating and set a $16.00 price target for the company in a report on Thursday, May 16th. Benchmark reissued a buy rating and issued a $15.00 price target on shares of Veeco Instruments in a report on Thursday, May 16th. Finally, BidaskClub downgraded shares of Veeco Instruments from a hold rating to a sell rating in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $14.25.

Shares of NASDAQ:VECO opened at $11.77 on Thursday. The firm has a fifty day moving average price of $11.78. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.34 and a current ratio of 3.32. Veeco Instruments has a one year low of $6.27 and a one year high of $15.00. The company has a market cap of $581.18 million, a P/E ratio of -294.25 and a beta of 1.24.

Veeco Instruments (NASDAQ:VECO) last announced its quarterly earnings results on Monday, May 6th. The semiconductor company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.09. Veeco Instruments had a negative net margin of 84.86% and a negative return on equity of 3.17%. The firm had revenue of $99.37 million during the quarter, compared to the consensus estimate of $96.75 million. During the same period last year, the firm earned $0.20 EPS. The business’s quarterly revenue was down 37.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Veeco Instruments will post -0.41 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Veeco Instruments by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 565,660 shares of the semiconductor company’s stock valued at $4,191,000 after acquiring an additional 15,139 shares during the period. Two Sigma Investments LP boosted its stake in shares of Veeco Instruments by 197.3% during the 4th quarter. Two Sigma Investments LP now owns 124,389 shares of the semiconductor company’s stock valued at $922,000 after purchasing an additional 82,553 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Veeco Instruments during the 4th quarter valued at about $230,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Veeco Instruments by 387.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 15,672 shares of the semiconductor company’s stock valued at $116,000 after purchasing an additional 12,459 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan bought a new stake in shares of Veeco Instruments during the 4th quarter valued at about $102,000. Hedge funds and other institutional investors own 91.24% of the company’s stock.

Veeco Instruments Company Profile

Veeco Instruments Inc, together with its subsidiaries, develops, manufactures, sells, and supports semiconductor and thin film process equipment primarily to make electronic devices worldwide. It offers metal organic chemical vapor deposition systems; packaging lithography equipment; precision surface processing systems; laser annealing systems; ion beam deposition and etch systems; molecular beam epitaxy systems; 3D wafer inspection systems; and atomic layer deposition and other deposition systems.

Featured Story: How a Put Option Works

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Veeco Instruments Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Veeco Instruments and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Legato Capital Management LLC Purchases New Shares in UFP Technologies, Inc. (NASDAQ …

Acadian Asset Management LLC raised its position in UFP Technologies by 13.1% during the 1st quarter. Acadian Asset Management LLC now owns …

UFP Technologies logoLegato Capital Management LLC acquired a new position in shares of UFP Technologies, Inc. (NASDAQ:UFPT) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 46,820 shares of the industrial products company’s stock, valued at approximately $1,948,000.

A number of other institutional investors have also recently made changes to their positions in the business. Quantum Capital Management raised its position in UFP Technologies by 0.7% during the 1st quarter. Quantum Capital Management now owns 47,689 shares of the industrial products company’s stock worth $1,784,000 after buying an additional 335 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in UFP Technologies by 545.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,387 shares of the industrial products company’s stock worth $52,000 after buying an additional 1,172 shares during the last quarter. Acadian Asset Management LLC raised its position in UFP Technologies by 13.1% during the 1st quarter. Acadian Asset Management LLC now owns 11,430 shares of the industrial products company’s stock worth $428,000 after buying an additional 1,320 shares during the last quarter. Anchor Capital Advisors LLC raised its position in UFP Technologies by 4.5% during the 1st quarter. Anchor Capital Advisors LLC now owns 42,696 shares of the industrial products company’s stock worth $1,597,000 after buying an additional 1,831 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY purchased a new position in UFP Technologies during the 4th quarter worth $70,000. Institutional investors own 71.42% of the company’s stock.

Shares of UFP Technologies stock opened at $44.06 on Friday. The stock has a market cap of $306.59 million, a P/E ratio of 20.98 and a beta of 0.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.88 and a current ratio of 2.90. UFP Technologies, Inc. has a one year low of $27.80 and a one year high of $46.42. The stock’s fifty day moving average price is $41.30.

UFP Technologies (NASDAQ:UFPT) last announced its quarterly earnings data on Tuesday, May 7th. The industrial products company reported $0.50 EPS for the quarter, topping the Zacks’ consensus estimate of $0.40 by $0.10. UFP Technologies had a net margin of 8.35% and a return on equity of 11.79%. The company had revenue of $47.33 million during the quarter, compared to the consensus estimate of $45.10 million. As a group, equities analysts anticipate that UFP Technologies, Inc. will post 2.22 EPS for the current year.

In other news, CEO R Jeffrey Bailly sold 1,966 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $38.57, for a total transaction of $75,828.62. Following the transaction, the chief executive officer now directly owns 476,879 shares of the company’s stock, valued at approximately $18,393,223.03. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 16,219 shares of company stock worth $626,302. Corporate insiders own 11.00% of the company’s stock.

A number of equities analysts have commented on UFPT shares. BidaskClub upgraded shares of UFP Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, June 12th. ValuEngine upgraded shares of UFP Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Finally, Zacks Investment Research upgraded shares of UFP Technologies from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Tuesday, June 11th.

UFP Technologies Profile

UFP Technologies, Inc designs and converts foams, plastics, composites, and natural fiber materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts.

Featured Story: Discount Rate

Want to see what other hedge funds are holding UFPT?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UFP Technologies, Inc. (NASDAQ:UFPT).

Institutional Ownership by Quarter for UFP Technologies (NASDAQ:UFPT)

Receive News & Ratings for UFP Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for UFP Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Applied DNA Sciences (NASDAQ:APDN) Trading 11.1% Higher

Applied DNA Sciences Inc (NASDAQ:APDN)’s share price traded up 11.1% during mid-day trading on Tuesday . The stock traded as high as $0.33 …

Applied DNA Sciences logoApplied DNA Sciences Inc (NASDAQ:APDN)’s share price traded up 11.1% during mid-day trading on Tuesday . The stock traded as high as $0.33 and last traded at $0.30, 599,273 shares were traded during trading. An increase of 14% from the average session volume of 524,721 shares. The stock had previously closed at $0.27.

Separately, Maxim Group set a $3.00 price objective on shares of Biopharmx and gave the stock a “buy” rating in a research report on Wednesday, June 12th.

The stock has a 50-day moving average price of $0.49. The company has a current ratio of 1.24, a quick ratio of 1.10 and a debt-to-equity ratio of 2.82.

Applied DNA Sciences (NASDAQ:APDN) last released its quarterly earnings data on Thursday, May 9th. The technology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. Applied DNA Sciences had a negative net margin of 317.32% and a negative return on equity of 1,286.88%. The firm had revenue of $0.78 million during the quarter.

A number of institutional investors have recently added to or reduced their stakes in APDN. Capital Investment Advisors LLC acquired a new stake in Applied DNA Sciences during the second quarter worth about $27,000. Laurel Wealth Advisors Inc. purchased a new position in Applied DNA Sciences during the first quarter worth about $71,000. Finally, Creative Planning boosted its stake in Applied DNA Sciences by 194.6% during the first quarter. Creative Planning now owns 166,475 shares of the technology company’s stock worth $119,000 after buying an additional 109,966 shares during the period. Hedge funds and other institutional investors own 5.95% of the company’s stock.

About Applied DNA Sciences (NASDAQ:APDN)

Applied DNA Sciences, Inc develops and markets plat based or other DNA technology solution in the United States, Europe, and Asia. The company’s supply chain security and product authentication solutions include SigNature molecular tags that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNature T molecular tags, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs; and fiberTyping, a test of native cotton fiber DNA.

Recommended Story: Guidelines for Successful Channel Trading

Receive News & Ratings for Applied DNA Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Applied DNA Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Lexicon Pharmaceuticals (NASDAQ:LXRX) Lowered to Hold at Stifel Nicolaus

Two Sigma Investments LP raised its holdings in shares of Lexicon Pharmaceuticals by 70.0% during the 4th quarter. Two Sigma Investments LP now …

Lexicon Pharmaceuticals, Inc. logoStifel Nicolaus cut shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a buy rating to a hold rating in a research report released on Monday, BenzingaRatingsTable reports. They currently have $4.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $10.00.

LXRX has been the subject of a number of other research reports. Wedbush set a $175.00 target price on Lululemon Athletica and gave the company a hold rating in a report on Tuesday, June 11th. Needham & Company LLC lifted their target price on Alteryx to $108.00 and gave the company a buy rating in a report on Thursday, May 2nd. Zacks Investment Research raised HB Fuller from a sell rating to a hold rating in a report on Wednesday, July 3rd. BidaskClub lowered Westport Fuel Systems from a buy rating to a hold rating in a report on Friday, July 19th. Finally, ValuEngine lowered Wolverine World Wide from a hold rating to a sell rating in a report on Monday, May 20th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. Lexicon Pharmaceuticals currently has an average rating of Hold and an average target price of $14.88.

Shares of Lexicon Pharmaceuticals stock opened at $1.69 on Monday. Lexicon Pharmaceuticals has a 52-week low of $1.46 and a 52-week high of $12.58. The firm has a 50-day moving average price of $5.81. The company has a market cap of $604.69 million, a PE ratio of -1.48 and a beta of 0.84.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.21). The firm had revenue of $9.20 million during the quarter, compared to the consensus estimate of $13.26 million. The company’s revenue was down 63.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. As a group, sell-side analysts expect that Lexicon Pharmaceuticals will post -0.47 EPS for the current year.

A number of hedge funds have recently bought and sold shares of LXRX. Geode Capital Management LLC raised its holdings in shares of Lexicon Pharmaceuticals by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 565,085 shares of the biopharmaceutical company’s stock valued at $3,752,000 after purchasing an additional 13,664 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of Lexicon Pharmaceuticals by 70.0% during the 4th quarter. Two Sigma Investments LP now owns 313,877 shares of the biopharmaceutical company’s stock valued at $2,084,000 after purchasing an additional 129,215 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Lexicon Pharmaceuticals by 81.3% during the 4th quarter. Two Sigma Advisers LP now owns 28,416 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 12,739 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Lexicon Pharmaceuticals by 181.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 268,476 shares of the biopharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 173,096 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $173,000. 98.27% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: When can a hold rating present a buying opportunity?

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts